For the roughly 10,000 Americans whose brains were injured into a state of relentless, uncontrollable hunger, medicine has long offered only silence. This week, the FDA approved setmelanotide — sold as Imcivree by Rhythm Pharmaceuticals — as the first treatment ever cleared for acquired hypothalamic obesity, a condition born when tumors, strokes, or trauma sever the brain's ability to regulate appetite and energy. The drug, already proven in genetic obesity, now extends its reach to those whose suffering was not inherited but inflicted, closing a gap that had left patients and families cycling
Rhythm's Setmelanotide Wins FDA Approval as First Treatment for Acquired Hypothalamic Obesity
Patients with acquired hypothalamic obesity from brain tumors or strokes have previously had no approved treatment options, forcing families through repeated failed experimental approaches.
We now have hope that there is something that could work
Mark
What makes this condition so hard to treat before now?
Mimi
The hypothalamus is tiny and deeply embedded in the brain. When it's damaged, you're not just dealing with weight gain—you're fighting against the body's own regulatory system. There's no way to diet or exercise your way out of it. The hunger signal is broken at the source.
Mark
So the drug doesn't cure the brain damage itself?
Mimi
No. It works around it. By activating a specific pathway, it helps the brain suppress appetite and burn more energy despite the damage. It's a workaround, not a fix.
Mark
Why does this approval matter beyond the 10,000 patients who have it?
Mimi
Because it proves the problem is real and solvable. Once one drug works, other companies start asking: what else could work? It opens the research door. Right now, this condition is almost invisible in medicine.
Mark
What do families go through before this?
Mimi
Years of trying everything that doesn't work. Different diets, different medications, experimental protocols. Each failure is another loss of hope. Now they have something concrete to try.
Mark
Is this a cure?
Mimi
No. It's a treatment. The weight reduction in trials was significant—15.8 percent—but patients will need to keep taking it. It's a daily injection for life, most likely.
Mark
What happens next?
Mimi
The drug is available now. Doctors will start prescribing it. And other researchers will likely begin asking what else might help these patients. One approval can shift an entire field.
O Pulso
- Until this approval, some 10,000 Americans with hypothalamic obesity had no FDA-sanctioned treatment — only a succession of diets, off-label drugs, and experimental dead ends.
- The condition is unrelenting: a damaged hypothalamus cannot tell the body to stop storing fat or quiet the hunger signals, making weight gain feel biologically inevitable.
- In clinical trials, setmelanotide cut BMI by 15.8% over 52 weeks — compared to a 2.6% gain in the placebo group — a gap wide enough to represent genuine relief for patients and families.
- The drug activates the MC4R brain pathway to suppress appetite and boost energy burn, delivered as a once-daily injection patients can administer themselves.
- Rhythm Pharmaceuticals' shares jumped 6.6% on the news, with analysts projecting $34 million in hypothalamic obesity sales in 2026 alone — a signal that rare neurological conditions are attracting serious pharmaceutical attention.
- Advocates see this not just as a single treatment but as a proof of concept — one approval can shift how medicine, research, and investment orient themselves around a disease once considered untreatable.
For the roughly 10,000 Americans whose brains were injured into a state of relentless, uncontrollable hunger, medicine has long offered only silence. This week, the FDA approved setmelanotide — sold as Imcivree by Rhythm Pharmaceuticals — as the first treatment ever cleared for acquired hypothalamic obesity, a condition born when tumors, strokes, or trauma sever the brain's ability to regulate appetite and energy. The drug, already proven in genetic obesity, now extends its reach to those whose suffering was not inherited but inflicted, closing a gap that had left patients and families cycling through failed hopes for years.
On Thursday, the FDA approved the first-ever medication for acquired hypothalamic obesity — a rare and devastating condition in which brain injury from a tumor, stroke, or other trauma destroys the region responsible for regulating hunger and metabolism. The drug is setmelanotide, made by Rhythm Pharmaceuticals and marketed as Imcivree, and it became available to American patients immediately.
The hypothalamus is small but essential. When it is damaged, the body's hunger signals break down entirely — patients feel perpetually starved while their bodies store energy with relentless efficiency. Approximately 10,000 Americans live with this condition, and until this week, no approved treatment existed for them.
Setmelanotide works by activating the MC4R pathway in the brain, suppressing appetite and increasing energy expenditure through a once-daily injection. In the pivotal clinical trial, patients on the drug lost 15.8% of their BMI over 52 weeks, while the placebo group gained 2.6%. For families who had watched loved ones cycle through failed diets and experimental treatments, the approval represented something long denied: a real option.
Amy Wood of the Raymond A. Wood Foundation, an advocacy group for patients with this condition, captured the weight of the moment — not only as relief for those currently suffering, but as a signal that further treatments may follow. A single approval, she suggested, can open doors that were previously invisible.
Rhythm had already secured FDA clearance for Imcivree in genetic forms of obesity. This new indication extends the drug to those whose obesity was acquired through injury rather than inheritance. The company projects $290 million in total Imcivree sales in 2026, with $34 million attributed to the hypothalamic obesity indication. Shares rose 6.6% on the news. But the more durable measure of this moment belongs to the 10,000 Americans for whom medicine, until now, had no answer.
On Thursday, the FDA cleared the first medication ever approved to treat acquired hypothalamic obesity, a rare and devastating condition that strikes when brain injury—from a tumor, a stroke, or other trauma—damages the appetite control center and leaves patients unable to stop gaining weight. The drug is setmelanotide, made by Rhythm Pharmaceuticals and sold under the brand name Imcivree. It becomes available to American patients immediately.
The hypothalamus is a small but critical region of the brain. It tells you when you're hungry. It governs how fast your body burns calories and where it stores fat. When that region is damaged, the signals break. Patients experience relentless hunger and their bodies seem to work against them, storing energy with brutal efficiency. There are roughly 10,000 people living with this condition in the United States, and until this week, there was nothing a doctor could prescribe to help them.
Setmelanotide works by activating a specific pathway in the brain called MC4R, which helps suppress appetite and increase energy expenditure. Patients inject it once a day. In the late-stage clinical trial that won FDA approval, those who received the drug saw their weight drop by 15.8 percent as measured by body mass index over 52 weeks. The placebo group gained 2.6 percent. The difference is not subtle. For families who have watched their loved ones struggle through years of failed diets, failed medications, and failed experimental approaches, the approval feels like a door opening.
Amy Wood, who leads the Raymond A. Wood Foundation, an advocacy group for patients with this condition, described what families endure: a succession of "failed experiments," each one a hope that doesn't pan out. "We now have hope that there is something out there that could work for this condition," Wood said, "and also that it will hopefully open doors to other potential treatments in the future." That last part matters. A single approved treatment can shift how the medical and pharmaceutical world thinks about a disease. It signals that the problem is real, that solutions exist, that investment makes sense.
Rhythm Pharmaceuticals had already won FDA approval for Imcivree to treat genetic forms of obesity in children and adults as young as two years old. This new approval extends the drug into a different patient population—those whose obesity stems not from inherited genetic mutations but from acquired brain injury. The company estimates that in 2026, Imcivree will generate $290 million in total sales, with $34 million coming from the hypothalamic obesity indication alone. That projection reflects analyst Jonathan Wolleben's assessment at Citizens Bank.
The stock market responded positively. Rhythm's shares rose 6.6 percent in premarket trading on the news, closing at $96.34. But the real measure of this approval lies not in the market reaction but in what it means for the 10,000 Americans who have lived with a condition that medicine had no answer for. They now have one.
Citações Notáveis
Families with hypothalamic obesity patients have gone through repeated failed experiments, but now have hope that a treatment could work and may open doors to other potential therapies.— Amy Wood, executive director of the Raymond A. Wood Foundation
Quer a matéria completa?
Leia o original em Reuters ↗
Health & Medicine